Neuroblastoma is the most common extra-cranial malignant tumor in childhood. About 50% of the children have widespread metastatic diseases at initial diagnosis and the outcomes are poor. Chimeric antigen receptor (CAR) is a kind of genetically engineered receptors usually generated by extracellular antigen recognition region, spacer, transmembrane domain and intracellular endodomain. The antigen recognition region joining heavy and light chain variable regions of a monoclonal antibody with a linker to form a single-chain variable fragment (scFv) which can bind to tumor-associated antigens and lead to anti-tumor activity in an MHC-unrestricted manner. In this review, the recent advances and applications of CAR-T cell in neuroblostoma are reviewed and the application-related problems and possible solving strategies are discussed.